pharma · Advanced Solid Tumor · Acute Myeloid Leukemia or Myelodysplastic Syndromes · APRE
Aprea Therapeutics
Aprea Therapeutics clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US
- Employees
- 15
- Programs
- 15
- Drugs
- 5
- Patents
- 6
Aprea Therapeutics projects
15 ClinicalTrials.gov programs sponsored by Aprea Therapeutics.
Aprea Therapeutics has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
APR-246 + azacitidine
Aprea Therapeutics
MDS
1 trial -
APR-246
Aprea Therapeutics
Acute Myeloid Leukemia or Myelodysplastic Syndromes
1 trial -
APR-246
Aprea Therapeutics
Myelodysplastic Syndrome With Gene Mutation
1 trial -
APR-246
Aprea Therapeutics
Melanoma
1 trial -
APR-246
Aprea Therapeutics
Myelodysplastic Syndrome
1 trial -
APR-246
Aprea Therapeutics
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
1 trial -
APR-246
Aprea Therapeutics
High-grade Serous Ovarian Cancer
1 trial -
APR-246 (eprenetapopt) + Acalabrutinib in CLL
Aprea Therapeutics
Non Hodgkin Lymphoma
1 trial -
APR-246 (eprenetapopt) + Pembrolizumab
Aprea Therapeutics
Bladder Cancer
1 trial -
ATRN-119
Aprea Therapeutics
HPV Positive Oropharyngeal Squamous Cell Carcinoma
1 trial -
ATRN-119
Aprea Therapeutics
Advanced Solid Tumor
1 trial -
APR-1051
Aprea Therapeutics
Advanced Solid Tumor
1 trial -
APR-246
Aprea Therapeutics
Hematologic Neoplasms
1 trial -
APR-246
Aprea Therapeutics
Myeloid Malignancy
1 trial -
APR-548 + Azacitidine
Aprea Therapeutics
MDS
1 trial
Frequently asked questions
How many clinical projects does Aprea Therapeutics have?
15 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.